Adding a fourth oral antidiabetic drug to a triple regimen beats metformin dose escalation for achieving glycemic control.

We look forward to presenting important new data for Afrezza at this year’s ATTD and contributing to the scientific dialogue around meal-time diabetes management across both adult and pediatric ...